Memory and Frontal Lobe Dysfunction in Schizophrenia and Schizoaffective Disorder

Beatty, William W.; Jocic, Zeljko; Monson, Nancy; Staton, R. Dennis

doi:10.1097/00005053-199307000-00008

Cited by 95 publications

(55 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Diffuse white matter pathology is likely to negatively impact virtually all aspects of cognitive functioning and consistent with this possibility, deficits in executive functioning, speed of information processing, attention, and retrospective memory have been identified (Beatty et al, 1989;Beatty et al, 1993;Griffiths et al, 2005;Henry & Beatty, 2006). However, deficits in memory are among the most consistently reported findings, and in their meta-analytic review of short-term, long-term, and working memory, Thornton and Raz (1997) concluded that MS is associated with significant impairment on all three types of retrospective memory.…”

Section: Introductionmentioning

confidence: 82%

Prospective memory in multiple sclerosis

Rendell

Jensen

Henry

2007

J. Inter. Neuropsych. Soc.

View full text Add to dashboard Cite

There is considerable evidence that multiple sclerosis (MS) is associated with impaired retrospective memory. However, although preliminary evidence suggests that prospective memory is also affected by the disorder, the degree and nature of the impairment remains to be clarified. Twenty participants with MS were compared with 20 matched controls on Virtual Week, a measure of prospective memory that closely represents the types of prospective memory tasks that actually occur in everyday life, and provides an opportunity to investigate the different sorts of prospective memory failures that occur. The results indicated that irrespective of the specific prospective memory task demands, MS participants' performance was significantly impaired relative to controls. MS deficits could not be attributed to problems with retrospective memory because MS participants in the present study did not differ significantly from controls on measures of long-and short-term memory, and significant impairment was observed on a prospective memory task, which imposed only minimal demands on retrospective memory. These results therefore suggest that individuals with MS may experience general difficulties with prospective memory. The practical and theoretical implications of these findings are discussed. (JINS, 2007, 13, 410-416.)

show abstract

Section: Introductionmentioning

confidence: 82%

Prospective memory in multiple sclerosis

Rendell

Jensen

Henry

2007

J. Inter. Neuropsych. Soc.

View full text Add to dashboard Cite

show abstract

“…44 Finally, frontal lobe abnormalities, which are a hallmark of ASD, have also been found in other neurodevelopmental disorders such as schizophrenia. 45 These fi ndings suggest that phenotypic similarities in brain anatomy between ASD and other psychiatric disorders might be related to similarities in their respective clinical phenotypes. However, future research is needed to establish the extent and origins of such shared neuroanatomical variation, and to establish whether there are common or distinct genetic and molecular mechanisms for similar symptoms across disorders.…”

Section: Neural Systems Underlying Autistic Symptoms and Traitsmentioning

confidence: 94%

Neuroimaging in autism spectrum disorder: brain structure and function across the lifespan

Ecker

Bookheimer

Murphy

2015

The Lancet Neurology

379

281

View full text Add to dashboard Cite

Over the past decade, in-vivo MRI studies have provided many invaluable insights into the neural substrates underlying autism spectrum disorder (ASD), which is now known to be associated with neurodevelopmental variations in brain anatomy, functioning, and connectivity. These systems-level features of ASD pathology seem to develop diff erentially across the human lifespan so that the cortical abnormalities that occur in children with ASD diff er from those noted at other stages of life. Thus, investigation of the brain in ASD poses particular methodological challenges, which must be addressed to enable the comparison of results across studies. Novel analytical approaches are also being developed to facilitate the translation of fi ndings from the research to the clinical setting. In the future, the insights provided by human neuroimaging studies could contribute to biomarker development for ASD and other neurodevelopmental disorders, and to new approaches to diagnosis and treatment.

show abstract

“…In the few studies examining neurocognition, memory impairments are reported to be greater in SZ than in SA groups. 16,17 Apart from emerging evidence suggesting that adults with SA perform better on measures of social cognition, there are few, if any, additional reliable differences in cognitive functioning between these diagnostic groups. 18,19 In the available studies of youth with early-onset schizophrenia spectrum disorders (EOSS), children and adolescents have evidenced generalized neurocognitive deficits compared with healthy community controls.…”

Section: Introductionmentioning

confidence: 99%

“…[13][14][15][16] Individuals with the bipolar subtype of SA appear to have better outcomes than individuals with the depressive subtype. In the few studies examining neurocognition, memory impairments are reported to be greater in SZ than in SA groups.…”

Section: Introductionmentioning

confidence: 99%

Neurocognition in Early-Onset Schizophrenia and Schizoaffective Disorders

Hooper¹,

Giuliano²,

Youngstrom³

et al. 2010

Journal of the American Academy of Child & Adolescent Psych

View full text Add to dashboard Cite

Objective-We examined the neuropsychological functioning of youth enrolled in the NIMH funded trial, Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS). We compared the baseline neuropsychological functioning of youth with schizophrenia (SZ, n = 79) to those with schizoaffective disorder (SA, n = 40), and examined the relationship of different variables of illness severity and adaptive behavior to neuropsychological functioning. ©2010 American Academy of Child and Adolescent PsychiatryCorrespondence to Dr. Stephen R. Hooper, Center for Development and Learning, CB# 7255, The Carolina Institute for Developmental Disabilities, University of North Carolina School of Medicine, Chapel Hill, NC 27599-7255; Stephen. hooper@cdl.unc.edu. The opinions and assertions contained in this report are the private views of the authors and are not to be construed as official or as reflecting the views of the Department of Health and Human Services, the National Institutes of Health, or the National Institute of Mental Health. Disclosure: Dr. Hooper receives or has received research support or served as a speaker/consultant for Eli Lilly and Sanofi-Aventis. Dr. Youngstrom has previously served on the Data Safety and Monitoring Board for Eli Lilly and consulted in the past with Otsuka. Dr. Sikich has a current financial interest and receives research funding or participates in clinical trials with Janssen, Pfizer, Bristol Myers-Squibb, Neuropharm, Curemark, and Seaside Pharmaceuticals. She also received software for a computer intervention in schizophrenia from Posit Science. In the past, Dr. Sikich received research funding from Eli Lilly, Janssen, Pfizer, Otsuka, and Astra Zeneca, and has served as a consultant for Sanofi Aventis and ABT Associates. Dr. Frazier receives or has received research support and acted as a consultant for Bristol-Myers Squibb Company, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Neuropharm, Otsuka America Pharmaceutical, and Pfizer. Dr. Findling receives or has received research support, acted as a consultant, and/or served on a speaker's bureau for Abbott, Addrenex, AstraZeneca, Biovail, Bristol-Myers Squibb, Forest, GlaxoSmithKline, Johnson & Johnson, KemPharm, Eli Lilly, Lundbeck, Neuropharm, Novartis, Organon, Otsuka, Pfizer, Sanofi-Aventis, Sepracore, Shire, Solvay, Supernus Pharmaceuticals, Validus, and Wyeth. Dr. McClellan has had past research support from Pfizer. Dr. Hamer has served as a consultant or advisor for Acadia, Cenerx, Corcept, Epix, Johnson & Johnson, NeuroPharmaBoost, Pepper-Hamil-ton, PureTechVentures, SanofiAventis, and Takeda. He has served on the advisory board for Enabled MD, Novartis, and Wyeth. He has served on a Data Safety Monitoring Board (DSMB) for Allergan, Eli Lilly & Company, Pfizer, Schwartz, and Solvey. He has served on a Mock Advisory Panel for Alpharma. He has served as a statistician on a University of North Carolina contract for a clinical trial with AstraZeneca. He has taught several seminars for SAS Institute. He has served as an expert...

show abstract

Memory and Frontal Lobe Dysfunction in Schizophrenia and Schizoaffective Disorder

Cited by 95 publications

References 0 publications

Prospective memory in multiple sclerosis

Prospective memory in multiple sclerosis

Neuroimaging in autism spectrum disorder: brain structure and function across the lifespan

Neurocognition in Early-Onset Schizophrenia and Schizoaffective Disorders

Contact Info

Product

Resources

About